ClinicalTrials.gg
CompletedNCT00663767Updated Feb 9, 2021

A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction

A Phase 2 interventional study of Placebo; oral and Placebo; oral in Dental Pain, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-09.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Toothache with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Toothache · United States.

Enrollment
18th of 50
250 · median 194
Started
2008
with 2 others
Phase 2
20 of 54
none open now
Registered
6th of 54
by date
Lead sponsor
3 of 54
Pfizer

Among the 54 studies in Toothache with a site in United States, this one is the 18th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2008, is one of 20 in phase 2, and was the 6th registered.

Toothache

142 studies on the registry are indexed under Toothache; 28 are open to participants now.

Browse Toothache studies →

Open to participants now

6 of the 54 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Toothache with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 study designed to test the ability of investigational study drug ARRY-371797 to reduce pain in a postoperative pain model (third molar extraction), and to further evaluate the drug's safety. Approximately 250 subjects from the US will be enrolled in this study.

03

Conditions studied

  • Dental Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Scheduled for outpatient oral surgical procedure to remove 3 or more third molars, at least 1 of which is mandibular and fully or partially impacted by bone.
  • Females of must be willing to use an acceptable method of within 14 days prior to first dose of study drug until the completion of the follow-up procedures.
  • Body weight >50 kg (110 lbs).
  • Good health determined by medical history, physical examination, vital signs and clinical laboratory results of non-clinical significance.
  • Additional criteria exist.

Key Exclusion Criteria:

  • Evidence or history of dermatologic, hematological, renal, endocrine (e.g. poorly controlled diabetes), pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, ophthalmologic, or allergic disease (including clinically significant drug allergies that could impact the conduct of this study, but excluding untreated, asymptomatic, seasonal allergies at time of study drug dosing).
  • Positive urine drug screen within 28 days prior to first dose of study drug.
  • Use of prohibited prescription drugs, or grapefruit juice within 7 days of first dose of study drug; prohibited medications are defined as nonsteroidal and steroidal antiinflammatory drugs, analgesics including opioids (except low dose aspirin for myocardial infarction prophylaxis), P450 substrates or inhibitors (strong or moderate).
  • Additional criteria exist.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo; oral

  • Experimental
    Placebo, ARRY-371797

    Drug: Placebo; oral · Drug: ARRY-371797, p38 inhibitor; oral

  • Experimental
    ARRY-371797, Placebo

    Drug: ARRY-371797, p38 inhibitor; oral · Drug: Placebo; oral

  • Experimental
    ARRY-371797

    Drug: ARRY-371797, p38 inhibitor; oral

  • Active comparator
    Celecoxib, Placebo

    Drug: Celecoxib, COX-2 inhibitor; oral · Drug: Placebo; oral

  • Experimental
    Celecoxib, ARRY-371797

    Drug: Celecoxib, COX-2 inhibitor; oral · Drug: ARRY-371797, p38 inhibitor; oral

Interventions

06

What researchers measure

Primary outcomes

  1. Assess the efficacy of the study drug dosed postoperatively in terms of total pain relief (TOTPAR).

    Time frame: 6 hours post-dose

  2. Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, electrocardiograms and vital signs.

    Time frame: Duration of study

Secondary outcomes

  1. Assess the efficacy of the study drug (versus placebo and celecoxib) in terms of pain relief measurements [including TOTPAR, total pain intensity (TPI) and time to rescue medication].

    Time frame: Duration of study

07

Study locations

2 sites
  • PPD Phase I Clinic
    Austin, Texas 78744, United States
  • Lifetree Clinical Research
    Salt Lake City, Utah 84106, United States
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2008 to primary completion in Jun 2008, 2 months.

Of 10 phase 2 interventional studies under Toothache, half reached primary completion within 3 months of starting (the median); a quarter within 3 and three quarters within 5. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2008
First posted
Apr 22, 2008
StartActual
Apr 7, 2008
Primary completionActual
Jun 20, 2008
CompletionActual
Jun 20, 2008
Results delay requested
Dec 9, 2009
Last update
Feb 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00663767
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 22, 2008
Start date
Apr 7, 2008
Primary completion
Jun 20, 2008
Completion
Jun 20, 2008
Last update
Feb 9, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Emprumapimod · Celecoxib · COX-2 inhibitors

Start the discussion